Walleye Capital’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-15,568
Closed -$378K – 6119
2026
Q2
$378K Buy
+15,568
New +$265K ﹤0.01% 2982
2026
Q1
– Sell
-74,869
Closed -$1.42M – 4781
2025
Q4
$1.42M Buy
+74,869
New +$1.08M ﹤0.01% 2155
2025
Q3
– Sell
-62,298
Closed -$710K – 4920
2025
Q2
$710K Sell
62,298
-11,762
-16% -$127K ﹤0.01% 2335
2025
Q1
$880K Buy
+74,060
New +$1.24M ﹤0.01% 2077
2024
Q3
– Sell
-24,882
Closed -$519K – 5701
2024
Q2
$519K Buy
+24,882
New +$387K ﹤0.01% 3482
2021
Q4
– Sell
-10,546
Closed -$316K – 2249
2021
Q3
$316K Buy
+10,546
New +$325K 0.01% 990

Other funds holding NRIX

Walleye Capital's NRIX Position: Q3 2026 in Review

Walleye Capital sold out of Nurix Therapeutics (NRIX) in Q3 2026, closing a stake of 15,568 shares — an estimated $378K sold.

Walleye Capital first reported a position in NRIX in Q3 2021 and held it in 6 quarters. The position peaked at $1.42M in Q4 2025. 186 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Walleye Capital reported no remaining Nurix Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Walleye Capital sold 15,568 Nurix Therapeutics shares in Q3 2026, an estimated $378K.
  • Walleye Capital first reported a position in Nurix Therapeutics in Q3 2021 and held it in 6 quarters.
  • Walleye Capital's Nurix Therapeutics position peaked at $1.42M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.